<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medication overuse headache: Etiology, clinical features, and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medication overuse headache: Etiology, clinical features, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Medication overuse headache: Etiology, clinical features, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ivan Garza, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd J Schwedt, MD, MSCI</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerry W Swanson, MD, MHPE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic daily headache is a descriptive term that encompasses several different specific headache diagnoses. Primary chronic daily headache types of long duration (ie, four hours or more) include chronic migraine, chronic tension-type headache, hemicrania continua, and new daily persistent headache. Medication overuse headache (MOH), a secondary headache disorder, frequently complicates management of primary headache disorders and other secondary headache disorders. (See  <a class="medical medical_review" href="/d/html/3333.html" rel="external">"Chronic daily headache: Associated syndromes, evaluation, and management"</a>.)</p><p>Although not a primary type of chronic daily headache, MOH frequently coexists with primary chronic daily headache and other secondary headaches. MOH is among the top 20 causes of disability worldwide [<a href="#rid1">1</a>].</p><p>This topic will review the etiology, clinical features, and diagnosis of MOH. The treatment and prognosis of MOH is discussed separately. (See  <a class="medical medical_review" href="/d/html/3341.html" rel="external">"Medication overuse headache: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION AND TERMINOLOGY</span><span class="headingEndMark"> — </span>Medication overuse headache (MOH) is the term applied to headache occurring on 15 or more days per month developing as a consequence of regular overuse of acute headache medication for more than three months [<a href="#rid2">2</a>]. It usually, but not invariably, resolves after the overuse is stopped. MOH has also been termed analgesic rebound headache, drug-induced headache, and medication-misuse headache. The frequency of headache medication intake that constitutes overuse is defined by the diagnostic criteria for MOH, as listed in the table  (<a class="graphic graphic_table graphicRef71798" href="/d/graphic/71798.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H3"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Available evidence suggests many drugs used for the acute symptomatic treatment of headache can cause medication overuse headache (MOH) in individuals with primary or other secondary headache disorders [<a href="#rid3">3,4</a>]. The precise mechanisms that lead to MOH are still uncertain. However, multiple factors seem to play a role, including genetic predisposition, central sensitization, and biobehavioral factors.</p><p class="headingAnchor" id="H4"><span class="h2">Genetic predisposition</span><span class="headingEndMark"> — </span>Various studies and clinical observations suggest that MOH is restricted to individuals who already have other headache disorders [<a href="#rid3">3</a>]. Furthermore, MOH does not develop de novo in individuals with no previous headache history [<a href="#rid5">5</a>].</p><p>In a study of 103 patients using daily analgesics for arthritic pain but not for headache, only 8 patients (8 percent) had chronic daily headache, each of whom reported a previous history of episodic migraine [<a href="#rid6">6</a>]. This study supports the hypothesis that patients with previous episodic headaches may be susceptible to developing MOH and that analgesics may merely be a cofactor to the development of chronic daily headache in a genetically vulnerable individual.</p><p>Patients with migraine and tension-type headache seem to have the highest potential for MOH [<a href="#rid7">7</a>]. However, MOH has also been described in cluster headache [<a href="#rid8">8</a>] and in hemicrania continua [<a href="#rid9">9</a>].</p><p>In a 2018 systematic review, 33 genes with 50 polymorphisms were associated with an increased risk of MOH [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Central sensitization</span><span class="headingEndMark"> — </span>Investigations demonstrating facilitation of trigeminal pain processing in patients with chronic headache have suggested that central sensitization, the same process that occurs in migraine, can lead to MOH [<a href="#rid4">4,7,11</a>]. Daily exposure to some triptans can downregulate serotonin receptor subtypes 5-HT 1B and 5-HT 1D, and influence serotonin synthesis in the rat central nervous system [<a href="#rid3">3,12</a>].</p><p>In humans, chronic exposure to triptans and other analgesics could lead to downregulation of serotonin receptors and changes in central inhibitory pathways that translate to an impairment of antinociceptive activity and a permanent feeling of head pain [<a href="#rid3">3</a>]. In support of this argument, neurophysiologic studies have shown facilitation of trigeminal and somatic nociceptive systems in MOH primarily mediated at a supraspinal level [<a href="#rid13">13</a>]. Another study in rats found that sustained or repeated triptan treatment induced pro-nociceptive neural adaptations and enhanced responses to nitric oxide, a known trigger of migraine headache in humans [<a href="#rid14">14</a>]. In addition, a report that measured glucose metabolism in migraineurs with MOH using 18-F-fluorodeoxyglucose positron emission tomography (FDG-PET) demonstrated reversible metabolic change in pain processing structures and persistent orbitofrontal hypofunction [<a href="#rid15">15</a>].</p><p>Exposure to opiates also causes changes in the nervous system. Peripherally, the chronic administration of <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> results in increased expression of calcitonin gene-related peptide in primary afferent neurons [<a href="#rid16">16</a>]. Centrally, prolonged exposure to this opiate leads to increased descending facilitation from the rostral ventromedial medulla and increased excitatory neurotransmission at the level of the dorsal horn [<a href="#rid16">16</a>]. The combination of these may result in MOH [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Biobehavioral factors</span><span class="headingEndMark"> — </span>It has been proposed that MOH is a biobehavioral disorder [<a href="#rid17">17</a>]. Some patients may have compulsive drug seeking and drug taking behavior despite negative consequences, as the basis of MOH. Other patients may use opiates or other drugs with sedative/anxiolytic effects to treat both pain and a coexistent anxiety disorder [<a href="#rid17">17</a>].</p><p>Behaviors that may be particularly important in prompting and sustaining the overuse of medication include fear of headache, anticipatory anxiety, drug-taking behavior, and psychologic drug dependence [<a href="#rid17">17</a>]. In a prospective population-based longitudinal study of 32,067 adults from Norway, individuals using analgesics daily or weekly at baseline had a significantly increased risk of chronic pain 11 years later compared with those who never used analgesics [<a href="#rid18">18</a>]. People with chronic migraine had the highest risk (relative risk 13.3, 95% CI 9.3-19.1).</p><p>Further evidence that MOH is part of the spectrum of addictive disorders comes from the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>In a case-control study, patients with MOH derived from migraine (n = 41) had a significantly greater risk of substance-related disorders than those with episodic migraine (n = 41) (odds ratio 7.6, 95% CI 2.2-26) [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study of 1861 patients with chronic daily headache, 895 met criteria for probable MOH [<a href="#rid20">20</a>]. Substance dependence was significantly more frequent in patients with MOH than those without MOH (68 versus 20 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In research imaging studies, MOH is associated with atypical structure and function of brain regions that are commonly implicated in addiction, including regions of the mesocorticolimbic dopamine system [<a href="#rid21">21</a>]. </p><p></p><p class="headingAnchor" id="H7"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>The prevalence of medication overuse headache (MOH) in the general population is approximately 1 to 2 percent in most studies, and is higher in females than males [<a href="#rid3">3,4,11,22-28</a>]. Among patients who are seen at specialized headache centers, the prevalence of MOH is near 50 percent.</p><p>Migraine is the most common primary headache disorder associated with MOH. In a meta-analysis of 29 studies that included a total of 2612 patients with chronic MOH, the underlying primary headache type was migraine, tension-type, or mixed/other in 65, 27, and 8 percent, respectively [<a href="#rid29">29</a>].</p><p>In addition to medication overuse, history of substance disorders, anxiety, and depression may be risk factors for the evolution of migraine into MOH [<a href="#rid19">19,30</a>]. (See <a class="local">'Biobehavioral factors'</a> above.)</p><p>A low socioeconomic status may be another risk factor for the development of MOH in migraineurs [<a href="#rid31">31</a>].</p><p>Among those with migraine, the odds of medication overuse are increased with older age, smoking, symptoms of anxiety and depression, cutaneous allodynia, greater migraine symptom severity, and more intense head pain [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H8"><span class="h1">CAUSAL MEDICATIONS</span><span class="headingEndMark"> — </span>The frequency of headache medication intake that constitutes overuse is defined by the diagnostic criteria for MOH, as listed in the table  (<a class="graphic graphic_table graphicRef71798" href="/d/graphic/71798.html" rel="external">table 1</a>).</p><p>Many acute symptomatic medications used to treat headaches have the potential for causing MOH [<a href="#rid3">3</a>]. However, the degree of risk differs depending upon the specific medication or class of medications [<a href="#rid33">33</a>]. The risk of MOH appears to be highest with opioids, butalbital-containing combination analgesics, and <a class="drug drug_general" data-topicid="9192" href="/d/drug information/9192.html" rel="external">acetaminophen-aspirin-caffeine</a> combinations [<a href="#rid11">11,34</a>].</p><p class="headingAnchor" id="H1281534680"><span class="h2">Opioids and barbiturates</span><span class="headingEndMark"> — </span>A longitudinal population-based study that included 8219 subjects with episodic migraine (from a population sample of 120,000) showed that use of barbiturates (including butalbital) or opiates was associated with an approximate doubled risk of transformation from episodic to chronic migraine compared with patients taking <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> [<a href="#rid35">35</a>]. A 2008 review of clinic-based and population studies found that, for opiates, the increased risk was more pronounced in males, and the critical dose of exposure was approximately eight days a month [<a href="#rid35">35,36</a>]. For barbiturates, the critical dose of exposure was approximately five days a month and the effect appeared greater in females.</p><p>Butalbital-containing combination analgesic products are among the most common medications associated with MOH [<a href="#rid37">37</a>]. In a report of 169 patients from a tertiary headache center in New York who were followed for five years, butalbital-containing combination products were the most often associated with MOH, reported in 48 percent [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H2221481234"><span class="h2">Other analgesics</span><span class="headingEndMark"> — </span>The risk of MOH appears to be high with other combination analgesic medications, including <a class="drug drug_general" data-topicid="9192" href="/d/drug information/9192.html" rel="external">acetaminophen-aspirin-caffeine</a> combinations [<a href="#rid11">11,34</a>]. Simple analgesic medications are also among the most common medications associated with MOH, likely related to the frequency of used. In a trial that enrolled 610 patients with chronic migraine, the most commonly overused medications were simple analgesics (62 percent) and combination analgesics (41 percent), followed by triptans (21 percent) [<a href="#rid39">39</a>]. Patients taking opioids or butalbital-containing products were excluded. Similar results were found in a large cross-sectional study of more than 16000 patients with migraine, including nearly 3000 patients who met criteria for MOH [<a href="#rid40">40</a>]. Simple and combination analgesics were associated with MOH in 65 and 34 percent of cases, respectively.</p><p class="headingAnchor" id="H3938691878"><span class="h2">Nonsteroidal antiinflammatory medications</span><span class="headingEndMark"> — </span>There are conflicting data regarding nonsteroidal antiinflammatory drugs (NSAIDs), with the estimated risk of MOH from NSAIDs being low in most but not all studies [<a href="#rid35">35,36,38,41</a>]. Some studies have suggested that NSAIDs are protective against the development of chronic migraine for patients who have less than 10 headache days per month [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H3921039924"><span class="h2">Ergotamines</span><span class="headingEndMark"> — </span>The risk of MOH with ergotamines varies but appears to be decreasing due to decreased use associated with the introduction of new acute headache medications over time [<a href="#rid3">3</a>]. Until the mid-1990s, combination analgesics with <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a> or <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a> or with ergots combined with caffeine were the most frequently overused drugs associated with MOH in many European countries [<a href="#rid27">27</a>]. In a review of patients seen at a single headache center in the United States from 1990 to 2005, MOH secondary to <a class="drug drug_general" data-topicid="9416" href="/d/drug information/9416.html" rel="external">ergotamine</a> decreased while MOH secondary to triptans increased [<a href="#rid43">43</a>].</p><p>The risk of MOH with ergotamines may also reflect varying prescription patterns from country to country. In an analysis of 669 individuals with MOH in Europe and Latin America, ergotamines were overused by 4 percent of Europeans and 72 percent of Latin Americans [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H1264421663"><span class="h2">Triptans</span><span class="headingEndMark"> — </span>The estimated risk for MOH with triptans has varied among different studies, ranging from intermediate to low [<a href="#rid41">41</a>]. In a 2002 prospective German study of 98 patients with MOH, including 70 patients with migraine as the underlying primary headache type, overuse of triptans led to MOH sooner than overuse of ergots or analgesics and did so at a lower frequency of use [<a href="#rid45">45</a>]. The mean interval until onset of MOH was shortest for triptans (1.7 years), longer for ergots (2.7 years), and longest for analgesics (<a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a>, barbiturates, <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a> combinations; 4.8 years) [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H1428003117"><span class="h2">Other medications</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CGRP antagonists </strong>– Experience and data with calcitonin gene-related peptide (CGRP) antagonists are limited. However, preliminary data suggest CGRP antagonists may be unlikely to cause MOH [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ditans </strong>– The risk of MOH associated with selective serotonin 1F receptor agonists is uncertain, but experimental data suggest it may be similar to the risk associated with triptans [<a href="#rid46">46,47</a>].</p><p></p><p class="headingAnchor" id="H939412412"><span class="h2">Multiple medications</span><span class="headingEndMark"> — </span>It is often difficult to identify a single causal substance for MOH, since many patients are overusing more than one drug [<a href="#rid3">3,38</a>]. In the Brazilian study of 133 patients with transformed migraine and symptomatic medication overuse, the frequencies of patients overusing one, two, or three medication categories were 55, 41, and 4 percent, respectively [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H9"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The development of medication overuse headache (MOH) is typically preceded by an episodic headache disorder, typically migraine or tension-type headache, that has been treated with frequent and excessive amounts of acute symptomatic medications [<a href="#rid11">11</a>]. In clinical practice, MOH often manifests as a headache that is present or develops upon awakening [<a href="#rid11">11</a>]. Acute symptomatic treatment only provides transient relief, which leads to more acute symptomatic medication use.</p><p>The severity, location, and type of head pain with MOH can vary significantly among different individuals, but headache commonly occurs daily or nearly daily [<a href="#rid11">11</a>]. Nausea, asthenia, difficulty concentrating, memory problems, and irritability can accompany MOH [<a href="#rid11">11</a>].</p><p>To some extent, the clinical features of MOH may depend upon the type of headache medication that is overused [<a href="#rid45">45</a>]. In a prospective study of 98 patients with MOH, which included a majority of patients (71 percent) having migraine as the underlying type of headache, patients overusing ergots and analgesics (<a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a>, barbiturates, <a class="drug drug_general" data-topicid="9213" href="/d/drug information/9213.html" rel="external">caffeine</a> combinations) typically had a daily tension-type headache phenotype, while those with triptan-induced MOH were more likely to describe a daily migraine-like phenotype or an increase in migraine frequency [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H10"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of medication overuse headache (MOH) is based upon clinical impression. The course of the headache disorder and the history of drug intake and intake frequency are the only available methods of diagnosis. A history of analgesic use averaging more than two to three days per week in association with chronic daily headache supports the diagnosis of MOH. The diagnosis is made when there is a pattern of frequent headaches that fulfill diagnostic criteria for MOH listed below. (See <a class="local">'Diagnostic criteria'</a> below.)</p><p>Other disorders causing secondary headache must be excluded. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>In practice, some patients may be reluctant to fully disclose their medication history, particularly with regard to the frequency and amount consumed. In addition, it is not uncommon for patients to report prescription medications but not over-the-counter analgesics. In order to improve the accuracy of the medication history, it may be helpful to explain the concept of MOH to the patient, including the critical importance of medication use to development, diagnosis, and treatment of the disorder [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The diagnostic criteria for MOH  (<a class="graphic graphic_table graphicRef71798" href="/d/graphic/71798.html" rel="external">table 1</a>) from the International Classification of Headache Disorders, 3rd edition (ICHD-3) are as follows [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Headache occurring on 15 or more days per month in a patient with a pre-existing headache disorder </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regular overuse for more than three months of one or more drugs that can be taken for acute and/or symptomatic treatment of headache:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Regular intake, for ≥10 days per month for &gt;3 months, of ergotamines, triptans, opioids, or combination analgesics, or any combination of ergotamines, triptans, simple analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs) and/or opioids without overuse of any single drug or drug class alone or when the pattern of overuse cannot be reliably established</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Regular intake, for ≥15 days per month for &gt;3 months, of simple analgesics (ie, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, or NSAID)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Not better accounted for by another ICHD-3 diagnosis</p><p></p><p>Patients who meet criteria for both medication overuse headache and chronic migraine are given both diagnoses [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/3337.html" rel="external">"Chronic migraine", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Any form of chronic daily headache, whether primary or secondary, needs to be considered in the differential diagnosis of MOH. Primary headache subtypes of chronic daily headache include chronic migraine, chronic tension-type headache, hemicrania continua, and new daily persistent headache. (See  <a class="medical medical_review" href="/d/html/3337.html" rel="external">"Chronic migraine"</a> and  <a class="medical medical_review" href="/d/html/3357.html" rel="external">"Tension-type headache in adults: Etiology, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3342.html" rel="external">"Hemicrania continua"</a> and  <a class="medical medical_review" href="/d/html/3343.html" rel="external">"New daily persistent headache"</a>.)</p><p>Other primary headache disorders, however, can also present as a chronic daily headache. The list includes cluster headache, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), hypnic headache, nummular headache, and chronic paroxysmal hemicrania. (See  <a class="medical medical_review" href="/d/html/3326.html" rel="external">"Cluster headache: Epidemiology, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3336.html" rel="external">"Short-lasting unilateral neuralgiform headache attacks: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3328.html" rel="external">"Hypnic headache"</a> and  <a class="medical medical_review" href="/d/html/3329.html" rel="external">"Nummular headache"</a> and  <a class="medical medical_review" href="/d/html/3334.html" rel="external">"Paroxysmal hemicrania: Clinical features and diagnosis"</a>.)</p><p>Appropriate diagnostic testing should be undertaken if clinical evaluation indicates the possibility of a serious medical or neurologic condition. (See  <a class="medical medical_review" href="/d/html/3349.html" rel="external">"Evaluation of headache in adults"</a> and  <a class="medical medical_review" href="/d/html/287.html" rel="external">"Evaluation of the adult with nontraumatic headache in the emergency department"</a>.)</p><p>A high frequency of drug intake does not mean that MOH is the only headache disorder that is present [<a href="#rid3">3</a>]. Typically, the patient with MOH has an underlying primary headache disorder (eg, migraine, tension-type headache) or secondary headache disorder that gradually or abruptly increased in frequency, which in turn led to an increased intake of analgesics and eventually to MOH superimposed upon the initial headache disorder. At this stage, patients may find themselves taking daily or frequent analgesics merely to prevent a disabling analgesic withdrawal headache [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H13"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15440.html" rel="external">"Patient education: Headaches in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/719.html" rel="external">"Patient education: Headache causes and diagnosis in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition </strong>– Medication overuse headache (MOH) is a headache occurring on 15 or more days per month developing as a consequence of regular overuse of acute or symptomatic headache medication for more than 3 months. It usually, but not invariably, resolves after the overuse is stopped. (See <a class="local">'Definition and terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology </strong>– The precise mechanisms that lead to MOH are still uncertain. However, multiple factors seem to play a role. These include (see <a class="local">'Pathophysiology'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetic predisposition</p><p class="bulletIndent2"><span class="glyph">•</span>Central sensitization of trigeminal pain processing</p><p class="bulletIndent2"><span class="glyph">•</span>Biobehavioral factors</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– The prevalence of MOH in the general population is approximately 1 to 2 percent and is higher in females than males. Migraine is the most common primary headache disorder associated with MOH. (See <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causal medications </strong>– Many acute symptomatic medications used to treat headaches have the potential for causing MOH. Estimates of the risk for MOH have varied across studies, but can be summarized as follows (see <a class="local">'Causal medications'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Highest with opioids, butalbital-containing combination analgesics, and <a class="drug drug_general" data-topicid="9192" href="/d/drug information/9192.html" rel="external">acetaminophen-aspirin-caffeine</a> combinations</p><p class="bulletIndent2"><span class="glyph">•</span>Intermediate to low with triptans</p><p class="bulletIndent2"><span class="glyph">•</span>Likely low with NSAIDs, although some studies suggest the risk could be high</p><p class="bulletIndent2"><span class="glyph">•</span>Uncertain but may be low risk with the calcitonin gene-related peptide antagonists</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– The development of MOH is typically preceded by an episodic headache disorder, usually migraine or tension-type headache, that has been treated with frequent and excessive amounts of acute symptomatic medications. MOH commonly occurs daily or nearly daily. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of MOH is based upon clinical impression. A history of symptomatic medication use averaging more than two to three days per week in association with chronic daily headache is suggestive. The diagnosis is made when the pattern of frequent headaches fulfills the diagnostic criteria for MOH  (<a class="graphic graphic_table graphicRef71798" href="/d/graphic/71798.html" rel="external">table 1</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– The management of MOH is discussed separately. (See  <a class="medical medical_review" href="/d/html/3341.html" rel="external">"Medication overuse headache: Treatment and prognosis"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388:1545.</a></li><li><a class="nounderline abstract_t">Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1.</a></li><li><a class="nounderline abstract_t">Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol 2004; 3:475.</a></li><li><a class="nounderline abstract_t">Abrams BM. Medication overuse headaches. Med Clin North Am 2013; 97:337.</a></li><li><a class="nounderline abstract_t">Lance F, Parkes C, Wilkinson M. Does analgesic abuse cause headaches de novo? Headache 1988; 28:61.</a></li><li><a class="nounderline abstract_t">Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache 2003; 43:179.</a></li><li><a class="nounderline abstract_t">Katsarava Z, Jensen R. Medication-overuse headache: where are we now? Curr Opin Neurol 2007; 20:326.</a></li><li><a class="nounderline abstract_t">Paemeleire K, Bahra A, Evers S, et al. Medication-overuse headache in patients with cluster headache. Neurology 2006; 67:109.</a></li><li><a class="nounderline abstract_t">Young WB, Silberstein SD. Hemicrania continua and symptomatic medication overuse. Headache 1993; 33:485.</a></li><li><a class="nounderline abstract_t">Cargnin S, Viana M, Sances G, et al. A systematic review and critical appraisal of gene polymorphism association studies in medication-overuse headache. Cephalalgia 2018; 38:1361.</a></li><li><a class="nounderline abstract_t">Dodick D, Freitag F. Evidence-based understanding of medication-overuse headache: clinical implications. Headache 2006; 46 Suppl 4:S202.</a></li><li><a class="nounderline abstract_t">Dobson CF, Tohyama Y, Diksic M, Hamel E. Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain. Cephalalgia 2004; 24:2.</a></li><li><a class="nounderline abstract_t">Ayzenberg I, Obermann M, Nyhuis P, et al. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia 2006; 26:1106.</a></li><li><a class="nounderline abstract_t">De Felice M, Ossipov MH, Wang R, et al. Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol 2010; 67:325.</a></li><li><a class="nounderline abstract_t">Fumal A, Laureys S, Di Clemente L, et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 2006; 129:543.</a></li><li><a class="nounderline abstract_t">Boes CJ, Black DF, Dodick DW. Pathophysiology and management of transformed migraine and medication overuse headache. Semin Neurol 2006; 26:232.</a></li><li><a class="nounderline abstract_t">Saper JR, Hamel RL, Lake AE 3rd. Medication overuse headache (MOH) is a biobehavioural disorder. Cephalalgia 2005; 25:545.</a></li><li><a class="nounderline abstract_t">Zwart JA, Dyb G, Hagen K, et al. Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology 2003; 61:160.</a></li><li><a class="nounderline abstract_t">Radat F, Creac'h C, Swendsen JD, et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia 2005; 25:519.</a></li><li><a class="nounderline abstract_t">Fuh JL, Wang SJ, Lu SR, Juang KD. Does medication overuse headache represent a behavior of dependence? Pain 2005; 119:49.</a></li><li><a class="nounderline abstract_t">Schwedt TJ, Chong CD. Medication Overuse Headache: Pathophysiological Insights from Structural and Functional Brain MRI Research. Headache 2017.</a></li><li><a class="nounderline abstract_t">Pascual J, Colás R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Rep 2001; 5:529.</a></li><li><a class="nounderline abstract_t">Westergaard ML, Hansen EH, Glümer C, et al. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia 2014; 34:409.</a></li><li><a class="nounderline abstract_t">Steiner TJ, Stovner LJ, Katsarava Z, et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain 2014; 15:31.</a></li><li><a class="nounderline abstract_t">Zwart JA, Dyb G, Hagen K, et al. Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology 2004; 62:1540.</a></li><li><a class="nounderline abstract_t">Castillo J, Muñoz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache 1999; 39:190.</a></li><li class="breakAll">Diener HC, Limmroth V, Katsarava Z. Medication-Overuse Headache. In: Chronic daily headache for clinicians, Goadsby PJ, Dodick DW (Eds), Decker, Hamilton 2005. p.117.</li><li><a class="nounderline abstract_t">Obermann M, Katsarava Z. Management of medication-overuse headache. Expert Rev Neurother 2007; 7:1145.</a></li><li class="breakAll">Diener HC, Dahlof CG. Headache associated with chronic use of substances. In: The Headaches, Second ed, Olesen J, Tfelt-Hansen P, Welch KM (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.871.</li><li><a class="nounderline abstract_t">Hird MA, Sandoe CH. Medication Overuse Headache: an Updated Review and Clinical Recommendations on Management. Curr Neurol Neurosci Rep 2023; 23:389.</a></li><li><a class="nounderline abstract_t">Atasoy HT, Unal AE, Atasoy N, et al. Low income and education levels may cause medication overuse and chronicity in migraine patients. Headache 2005; 45:25.</a></li><li><a class="nounderline abstract_t">Schwedt TJ, Alam A, Reed ML, et al. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain 2018; 19:38.</a></li><li><a class="nounderline abstract_t">Ljubisavljevic S, Ljubisavljevic M, Damjanovic R, Kalinic S. A Descriptive Review of Medication-Overuse Headache: From Pathophysiology to the Comorbidities. Brain Sci 2023; 13.</a></li><li><a class="nounderline abstract_t">Johnson JL, Hutchinson MR, Williams DB, Rolan P. Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment. Cephalalgia 2013; 33:52.</a></li><li><a class="nounderline abstract_t">Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48:1157.</a></li><li><a class="nounderline abstract_t">Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology 2008; 71:1821.</a></li><li><a class="nounderline abstract_t">Saper JR, Da Silva AN. Medication overuse headache: history, features, prevention and management strategies. CNS Drugs 2013; 27:867.</a></li><li><a class="nounderline abstract_t">Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes. Cephalalgia 2004; 24:483.</a></li><li><a class="nounderline abstract_t">Schwedt TJ, Hentz JG, Sahai-Srivastava S, et al. Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial. Headache 2021; 61:351.</a></li><li><a class="nounderline abstract_t">Schwedt TJ, Buse DC, Argoff CE, et al. Medication Overuse and Headache Burden: Results From the CaMEO Study. Neurol Clin Pract 2021; 11:216.</a></li><li><a class="nounderline abstract_t">Thorlund K, Sun-Edelstein C, Druyts E, et al. Risk of medication overuse headache across classes of treatments for acute migraine. J Headache Pain 2016; 17:107.</a></li><li><a class="nounderline abstract_t">Lipton RB, Serrano D, Nicholson RA, et al. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2013; 53:1548.</a></li><li><a class="nounderline abstract_t">Meskunas CA, Tepper SJ, Rapoport AM, et al. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache 2006; 46:766.</a></li><li><a class="nounderline abstract_t">Find NL, Terlizzi R, Munksgaard SB, et al. Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study. J Headache Pain 2015; 17:20.</a></li><li><a class="nounderline abstract_t">Limmroth V, Katsarava Z, Fritsche G, et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59:1011.</a></li><li><a class="nounderline abstract_t">Saengjaroentham C, Strother LC, Dripps I, et al. Differential medication overuse risk of novel anti-migraine therapeutics. Brain 2020; 143:2681.</a></li><li><a class="nounderline abstract_t">Rau JC, Navratilova E, Oyarzo J, et al. Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache. Cephalalgia 2020; 40:903.</a></li><li><a class="nounderline abstract_t">Krymchantowski AV. Overuse of symptomatic medications among chronic (transformed) migraine patients: profile of drug consumption. Arq Neuropsiquiatr 2003; 61:43.</a></li></ol></div><div id="topicVersionRevision">Topic 3340 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27733282" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29368949" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15261608" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Medication-overuse headache: a worldwide problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23419631" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Medication overuse headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3343127" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Does analgesic abuse cause headaches de novo?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12603636" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Does chronic daily headache arise de novo in association with regular use of analgesics?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17495628" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Medication-overuse headache: where are we now?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16832088" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Medication-overuse headache in patients with cluster headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8262795" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hemicrania continua and symptomatic medication overuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28870085" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A systematic review and critical appraisal of gene polymorphism association studies in medication-overuse headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17078852" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Evidence-based understanding of medication-overuse headache: clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14687006" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16919061" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20373344" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Triptan-induced latent sensitization: a possible basis for medication overuse headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16330505" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16628534" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pathophysiology and management of transformed migraine and medication overuse headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15955043" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Medication overuse headache (MOH) is a biobehavioural disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12874392" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15955038" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Psychiatric comorbidity in the evolution from migraine to medication overuse headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16298069" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Does medication overuse headache represent a behavior of dependence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28160280" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Medication Overuse Headache: Pathophysiological Insights from Structural and Functional Brain MRI Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11676887" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Epidemiology of chronic daily headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24293089" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24884549" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The impact of headache in Europe: principal results of the Eurolight project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15136678" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Analgesic overuse among subjects with headache, neck, and low-back pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613213" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Kaplan Award 1998. Epidemiology of chronic daily headache in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613213" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Kaplan Award 1998. Epidemiology of chronic daily headache in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868013" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Management of medication-overuse headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868013" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Management of medication-overuse headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37271793" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Medication Overuse Headache: an Updated Review and Clinical Recommendations on Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15663609" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Low income and education levels may cause medication overuse and chronicity in migraine patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29797100" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37891777" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A Descriptive Review of Medication-Overuse Headache: From Pathophysiology to the Comorbidities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23144180" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18808500" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19029522" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Excessive acute migraine medication use and migraine progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23925669" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Medication overuse headache: history, features, prevention and management strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15154858" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33432635" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34476122" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Medication Overuse and Headache Burden: Results From the CaMEO Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27882516" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Risk of medication overuse headache across classes of treatments for acute migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23992516" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16643579" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26957090" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12370454" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Features of medication overuse headache following overuse of different acute headache drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32810212" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Differential medication overuse risk of novel anti-migraine therapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32580575" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12715017" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Overuse of symptomatic medications among chronic (transformed) migraine patients: profile of drug consumption.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
